Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 282

1.

Reduced threshold for store overload-induced Ca2+ release is a common defect of RyR1 mutations associated with malignant hyperthermia and central core disease.

Chen W, Koop A, Liu Y, Guo W, Wei J, Wang R, MacLennan DH, Dirksen RT, Chen SRW.

Biochem J. 2017 Aug 7;474(16):2749-2761. doi: 10.1042/BCJ20170282.

2.

Metformin increases degradation of phospholamban via autophagy in cardiomyocytes.

Teng AC, Miyake T, Yokoe S, Zhang L, Rezende LM Jr, Sharma P, MacLennan DH, Liu PP, Gramolini AO.

Proc Natl Acad Sci U S A. 2015 Jun 9;112(23):7165-70. doi: 10.1073/pnas.1508815112. Epub 2015 May 26.

3.

Muscle spindles exhibit core lesions and extensive degeneration of intrafusal fibers in the Ryr1(I4895T/wt) mouse model of core myopathy.

Zvaritch E, MacLennan DH.

Biochem Biophys Res Commun. 2015 Apr 24;460(1):34-9. doi: 10.1016/j.bbrc.2015.01.056. Epub 2015 Jan 22.

PMID:
25619131
4.

Exome analysis identifies Brody myopathy in a family diagnosed with malignant hyperthermia susceptibility.

Sambuughin N, Zvaritch E, Kraeva N, Sizova O, Sivak E, Dickson K, Weglinski M, Capacchione J, Muldoon S, Riazi S, Hamilton S, Brandom B, MacLennan DH.

Mol Genet Genomic Med. 2014 Nov;2(6):472-83. doi: 10.1002/mgg3.91. Epub 2014 Jun 6.

5.

Type 2 ryanodine receptor domain A contains a unique and dynamic α-helix that transitions to a β-strand in a mutant linked with a heritable cardiomyopathy.

Amador FJ, Kimlicka L, Stathopulos PB, Gasmi-Seabrook GM, Maclennan DH, Van Petegem F, Ikura M.

J Mol Biol. 2013 Nov 1;425(21):4034-46. doi: 10.1016/j.jmb.2013.08.015. Epub 2013 Aug 23.

PMID:
23978697
6.

CASQ1 gene is an unlikely candidate for malignant hyperthermia susceptibility in the North American population.

Kraeva N, Zvaritch E, Frodis W, Sizova O, Kraev A, MacLennan DH, Riazi S.

Anesthesiology. 2013 Feb;118(2):344-9. doi: 10.1097/01.anes.0000530185.78660.da. Erratum in: Anesthesiology. 2018 Mar;128(3):692.

PMID:
23460944
7.

Novel excitation-contraction uncoupled RYR1 mutations in patients with central core disease.

Kraeva N, Zvaritch E, Rossi AE, Goonasekera SA, Zaid H, Frodis W, Kraev A, Dirksen RT, Maclennan DH, Riazi S.

Neuromuscul Disord. 2013 Feb;23(2):120-32. doi: 10.1016/j.nmd.2012.08.007. Epub 2012 Nov 24.

8.

Structural determination of the phosphorylation domain of the ryanodine receptor.

Sharma P, Ishiyama N, Nair U, Li W, Dong A, Miyake T, Wilson A, Ryan T, MacLennan DH, Kislinger T, Ikura M, Dhe-Paganon S, Gramolini AO.

FEBS J. 2012 Oct;279(20):3952-64. doi: 10.1111/j.1742-4658.2012.08755.x. Epub 2012 Sep 11.

9.

Type 1 ryanodine receptor knock-in mutation causing central core disease of skeletal muscle also displays a neuronal phenotype.

De Crescenzo V, Fogarty KE, Lefkowitz JJ, Bellve KD, Zvaritch E, MacLennan DH, Walsh JV Jr.

Proc Natl Acad Sci U S A. 2012 Jan 10;109(2):610-5. doi: 10.1073/pnas.1115111108. Epub 2011 Dec 27.

10.

Enhanced Ca2+ transport and muscle relaxation in skeletal muscle from sarcolipin-null mice.

Tupling AR, Bombardier E, Gupta SC, Hussain D, Vigna C, Bloemberg D, Quadrilatero J, Trivieri MG, Babu GJ, Backx PH, Periasamy M, MacLennan DH, Gramolini AO.

Am J Physiol Cell Physiol. 2011 Oct;301(4):C841-9. doi: 10.1152/ajpcell.00409.2010. Epub 2011 Jun 22.

11.

Ryanodine receptor type 1 gene mutations found in the Canadian malignant hyperthermia population.

Kraeva N, Riazi S, Loke J, Frodis W, Crossan ML, Nolan K, Kraev A, Maclennan DH.

Can J Anaesth. 2011 Jun;58(6):504-13. doi: 10.1007/s12630-011-9494-6. Epub 2011 Mar 31.

PMID:
21455645
12.

Identification of novel ryanodine receptor 1 (RyR1) protein interaction with calcium homeostasis endoplasmic reticulum protein (CHERP).

Ryan T, Sharma P, Ignatchenko A, MacLennan DH, Kislinger T, Gramolini AO.

J Biol Chem. 2011 May 13;286(19):17060-8. doi: 10.1074/jbc.M110.197186. Epub 2011 Mar 14.

13.

Muscle weakness in Ryr1I4895T/WT knock-in mice as a result of reduced ryanodine receptor Ca2+ ion permeation and release from the sarcoplasmic reticulum.

Loy RE, Orynbayev M, Xu L, Andronache Z, Apostol S, Zvaritch E, MacLennan DH, Meissner G, Melzer W, Dirksen RT.

J Gen Physiol. 2011 Jan;137(1):43-57. doi: 10.1085/jgp.201010523. Epub 2010 Dec 13.

14.

Mechanistic models for muscle diseases and disorders originating in the sarcoplasmic reticulum.

Maclennan DH, Zvaritch E.

Biochim Biophys Acta. 2011 May;1813(5):948-64. doi: 10.1016/j.bbamcr.2010.11.009. Epub 2010 Nov 27. Review.

15.

Constitutively active calcineurin induces cardiac endoplasmic reticulum stress and protects against apoptosis that is mediated by alpha-crystallin-B.

Bousette N, Chugh S, Fong V, Isserlin R, Kim KH, Volchuk A, Backx PH, Liu P, Kislinger T, MacLennan DH, Emili A, Gramolini AO.

Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18481-6. doi: 10.1073/pnas.1013555107. Epub 2010 Oct 11.

16.

Ca2+ dysregulation in Ryr1(I4895T/wt) mice causes congenital myopathy with progressive formation of minicores, cores, and nemaline rods.

Zvaritch E, Kraeva N, Bombardier E, McCloy RA, Depreux F, Holmyard D, Kraev A, Seidman CE, Seidman JG, Tupling AR, MacLennan DH.

Proc Natl Acad Sci U S A. 2009 Dec 22;106(51):21813-8. doi: 10.1073/pnas.0912126106. Epub 2009 Dec 3.

17.

Store overload-induced Ca2+ release as a triggering mechanism for CPVT and MH episodes caused by mutations in RYR and CASQ genes.

MacLennan DH, Chen SR.

J Physiol. 2009 Jul 1;587(Pt 13):3113-5. doi: 10.1113/jphysiol.2009.172155. Review. No abstract available.

18.

Crystal structure of type I ryanodine receptor amino-terminal beta-trefoil domain reveals a disease-associated mutation "hot spot" loop.

Amador FJ, Liu S, Ishiyama N, Plevin MJ, Wilson A, MacLennan DH, Ikura M.

Proc Natl Acad Sci U S A. 2009 Jul 7;106(27):11040-4. doi: 10.1073/pnas.0905186106. Epub 2009 Jun 18.

19.

Alterations of phospholamban function can exhibit cardiotoxic effects independent of excessive sarcoplasmic reticulum Ca2+-ATPase inhibition.

Schmitt JP, Ahmad F, Lorenz K, Hein L, Schulz S, Asahi M, Maclennan DH, Seidman CE, Seidman JG, Lohse MJ.

Circulation. 2009 Jan 27;119(3):436-44. doi: 10.1161/CIRCULATIONAHA.108.783506. Epub 2009 Jan 12.

PMID:
19139388
20.

Tbx5-dependent pathway regulating diastolic function in congenital heart disease.

Zhu Y, Gramolini AO, Walsh MA, Zhou YQ, Slorach C, Friedberg MK, Takeuchi JK, Sun H, Henkelman RM, Backx PH, Redington AN, Maclennan DH, Bruneau BG.

Proc Natl Acad Sci U S A. 2008 Apr 8;105(14):5519-24. doi: 10.1073/pnas.0801779105. Epub 2008 Mar 31.

21.

Comparative proteomics profiling of a phospholamban mutant mouse model of dilated cardiomyopathy reveals progressive intracellular stress responses.

Gramolini AO, Kislinger T, Alikhani-Koopaei R, Fong V, Thompson NJ, Isserlin R, Sharma P, Oudit GY, Trivieri MG, Fagan A, Kannan A, Higgins DG, Huedig H, Hess G, Arab S, Seidman JG, Seidman CE, Frey B, Perry M, Backx PH, Liu PP, MacLennan DH, Emili A.

Mol Cell Proteomics. 2008 Mar;7(3):519-33. Epub 2007 Nov 30.

22.

Interaction sites among phospholamban, sarcolipin, and the sarco(endo)plasmic reticulum Ca(2+)-ATPase.

Morita T, Hussain D, Asahi M, Tsuda T, Kurzydlowski K, Toyoshima C, Maclennan DH.

Biochem Biophys Res Commun. 2008 Apr 25;369(1):188-94. Epub 2007 Nov 29. Review.

PMID:
18053795
23.

An Ryr1I4895T mutation abolishes Ca2+ release channel function and delays development in homozygous offspring of a mutant mouse line.

Zvaritch E, Depreux F, Kraeva N, Loy RE, Goonasekera SA, Boncompagni S, Kraev A, Gramolini AO, Dirksen RT, Franzini-Armstrong C, Seidman CE, Seidman JG, Maclennan DH.

Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18537-42. Epub 2007 Nov 14. Erratum in: Proc Natl Acad Sci U S A. 2008 Jan 15;105(12):825. Boncompagi, Simona [corrected to Boncompagni, Simona].

24.

Analyzing the cardiac muscle proteome by liquid chromatography-mass spectrometry-based expression proteomics.

Gramolini AO, Kislinger T, Liu P, MacLennan DH, Emili A.

Methods Mol Biol. 2007;357:15-31.

25.

Cardiovascular proteomics: tools to develop novel biomarkers and potential applications.

Arab S, Gramolini AO, Ping P, Kislinger T, Stanley B, van Eyk J, Ouzounian M, MacLennan DH, Emili A, Liu PP.

J Am Coll Cardiol. 2006 Nov 7;48(9):1733-41. Epub 2006 Oct 17. Review.

26.

Cardiac-specific elevations in thyroid hormone enhance contractility and prevent pressure overload-induced cardiac dysfunction.

Trivieri MG, Oudit GY, Sah R, Kerfant BG, Sun H, Gramolini AO, Pan Y, Wickenden AD, Croteau W, Morreale de Escobar G, Pekhletski R, St Germain D, Maclennan DH, Backx PH.

Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):6043-8. Epub 2006 Apr 4.

27.

Cardiac-specific overexpression of sarcolipin in phospholamban null mice impairs myocyte function that is restored by phosphorylation.

Gramolini AO, Trivieri MG, Oudit GY, Kislinger T, Li W, Patel MM, Emili A, Kranias EG, Backx PH, Maclennan DH.

Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2446-51. Epub 2006 Feb 6.

28.

A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy.

Haghighi K, Kolokathis F, Gramolini AO, Waggoner JR, Pater L, Lynch RA, Fan GC, Tsiapras D, Parekh RR, Dorn GW 2nd, MacLennan DH, Kremastinos DT, Kranias EG.

Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1388-93. Epub 2006 Jan 23.

29.

Correlations between genotype and pharmacological, histological, functional, and clinical phenotypes in malignant hyperthermia susceptibility.

Monnier N, Kozak-Ribbens G, Krivosic-Horber R, Nivoche Y, Qi D, Kraev N, Loke J, Sharma P, Tegazzin V, Figarella-Branger D, Roméro N, Mezin P, Bendahan D, Payen JF, Depret T, Maclennan DH, Lunardi J.

Hum Mutat. 2005 Nov;26(5):413-25.

PMID:
16163667
30.

Interactions of the calcium ATPase with phospholamban and sarcolipin: structure, physiology and pathophysiology.

Maclennan DH.

J Muscle Res Cell Motil. 2004;25(8):600-1. No abstract available.

PMID:
16118852
32.

Proteome dynamics during C2C12 myoblast differentiation.

Kislinger T, Gramolini AO, Pan Y, Rahman K, MacLennan DH, Emili A.

Mol Cell Proteomics. 2005 Jul;4(7):887-901. Epub 2005 Apr 11.

33.

Ca2+ signaling in HEK-293 and skeletal muscle cells expressing recombinant ryanodine receptors harboring malignant hyperthermia and central core disease mutations.

Brini M, Manni S, Pierobon N, Du GG, Sharma P, MacLennan DH, Carafoli E.

J Biol Chem. 2005 Apr 15;280(15):15380-9. Epub 2005 Feb 2.

34.

Sarcolipin retention in the endoplasmic reticulum depends on its C-terminal RSYQY sequence and its interaction with sarco(endo)plasmic Ca(2+)-ATPases.

Gramolini AO, Kislinger T, Asahi M, Li W, Emili A, MacLennan DH.

Proc Natl Acad Sci U S A. 2004 Nov 30;101(48):16807-12. Epub 2004 Nov 19.

35.

HSP70 binds to the fast-twitch skeletal muscle sarco(endo)plasmic reticulum Ca2+ -ATPase (SERCA1a) and prevents thermal inactivation.

Tupling AR, Gramolini AO, Duhamel TA, Kondo H, Asahi M, Tsuchiya SC, Borrelli MJ, Lepock JR, Otsu K, Hori M, MacLennan DH, Green HJ.

J Biol Chem. 2004 Dec 10;279(50):52382-9. Epub 2004 Sep 14.

36.
37.

Cardiac-specific overexpression of sarcolipin inhibits sarco(endo)plasmic reticulum Ca2+ ATPase (SERCA2a) activity and impairs cardiac function in mice.

Asahi M, Otsu K, Nakayama H, Hikoso S, Takeda T, Gramolini AO, Trivieri MG, Oudit GY, Morita T, Kusakari Y, Hirano S, Hongo K, Hirotani S, Yamaguchi O, Peterson A, Backx PH, Kurihara S, Hori M, MacLennan DH.

Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9199-204. Epub 2004 Jun 16.

39.

Roles of conserved P domain residues and Mg2+ in ATP binding in the ground and Ca2+-activated states of sarcoplasmic reticulum Ca2+-ATPase.

McIntosh DB, Clausen JD, Woolley DG, MacLennan DH, Vilsen B, Andersen JP.

J Biol Chem. 2004 Jul 30;279(31):32515-23. Epub 2004 May 7.

41.

Identification of biochemical adaptations in hyper- or hypocontractile hearts from phospholamban mutant mice by expression proteomics.

Pan Y, Kislinger T, Gramolini AO, Zvaritch E, Kranias EG, MacLennan DH, Emili A.

Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2241-6.

42.

Detection of a novel ryanodine receptor subtype 1 mutation (R328W) in a malignant hyperthermia family by sequencing of a leukocyte transcript.

Loke JC, Kraev N, Sharma P, Du G, Patel L, Kraev A, MacLennan DH.

Anesthesiology. 2003 Aug;99(2):297-302.

PMID:
12883402
43.

Protocol for the sequence analysis of ryanodine receptor subtype 1 gene transcripts from human leukocytes.

Kraev N, Loke JC, Kraev A, MacLennan DH.

Anesthesiology. 2003 Aug;99(2):289-96.

PMID:
12883401
44.

Phospholamban: a crucial regulator of cardiac contractility.

MacLennan DH, Kranias EG.

Nat Rev Mol Cell Biol. 2003 Jul;4(7):566-77. Review.

PMID:
12838339
45.

The regulation of SERCA-type pumps by phospholamban and sarcolipin.

MacLennan DH, Asahi M, Tupling AR.

Ann N Y Acad Sci. 2003 Apr;986:472-80.

PMID:
12763867
46.

ATP binding residues of sarcoplasmic reticulum Ca2+-ATPase.

McIntosh DB, Clausen JD, Woolley DG, MacLennan DH, Vilsen B, Andersen JP.

Ann N Y Acad Sci. 2003 Apr;986:101-5.

PMID:
12763781
47.

Sarcolipin regulates sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA) by binding to transmembrane helices alone or in association with phospholamban.

Asahi M, Sugita Y, Kurzydlowski K, De Leon S, Tada M, Toyoshima C, MacLennan DH.

Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5040-5. Epub 2003 Apr 11.

48.

Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human.

Haghighi K, Kolokathis F, Pater L, Lynch RA, Asahi M, Gramolini AO, Fan GC, Tsiapras D, Hahn HS, Adamopoulos S, Liggett SB, Dorn GW 2nd, MacLennan DH, Kremastinos DT, Kranias EG.

J Clin Invest. 2003 Mar;111(6):869-76.

49.

Chronic SR Ca2+-ATPase inhibition causes adaptive changes in cellular Ca2+ transport.

Brittsan AG, Ginsburg KS, Chu G, Yatani A, Wolska BM, Schmidt AG, Asahi M, MacLennan DH, Bers DM, Kranias EG.

Circ Res. 2003 Apr 18;92(7):769-76. Epub 2003 Mar 13.

PMID:
12637367
50.

Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban.

Schmitt JP, Kamisago M, Asahi M, Li GH, Ahmad F, Mende U, Kranias EG, MacLennan DH, Seidman JG, Seidman CE.

Science. 2003 Feb 28;299(5611):1410-3.

Supplemental Content

Loading ...
Support Center